Changes in seroprevalence to hepatitis A in Victoria, Australia: a comparison of three time points.

Serological data provide an important measure of past exposure and immunity to hepatitis A virus (HAV) infection in a population. National serosurveys from developed countries have typically indicated a decline in HAV seroprevalence over time as sanitation levels improve. We examined trends in the seroepidemiology of HAV antibodies in Victoria, Australia, drawing on cross-sectional samples taken at three time points over a 20-year period.

The changing age distribution of men who have sex with men diagnosed with HIV in Victoria.

Objective: To describe recent trends among men who have sex with men (MSM) in age at diagnosis of HIV in Victoria.

Design And Setting: Analysis of Victorian HIV surveillance data from (i) passive surveillance (2000-2009) and (ii) the Victorian Primary Care Network for Sentinel Surveillance (VPCNSS) (2006-2009). Age-trend comparisons were made using syphilis and gonorrhoea enhanced surveillance.

Extremely prolonged HIV seroconversion associated with an MHC haplotype carrying disease susceptibility genes for antibody deficiency disorders.

Severe immunodeficiency during primary human immunodeficiency virus (HIV) infection is unusual. Here, we characterized viral and immunological parameters in a subject presenting with Pneumocystis jirovecii pneumonia in the setting of prolonged primary HIV illness and delayed seroconversion. HIV antibody was only detected by enzyme-linked immunosorbent assay 12 months after presentation, and Western blot profiles remain indeterminate.

The impact of immigration on the burden of HIV infection in Victoria, Australia.

Background: Accurate estimates of the number of people diagnosed and living with HIV infection within a health jurisdiction provide the basis for planning of clinical service provision. Case reporting of new diagnoses does not account for inwards and outwards migration of people with HIV infection, thereby providing an inaccurate basis for planning.

Methods: The Victorian passive surveillance system records all cases of HIV diagnosed in Victoria and distinguishes between new Victorian diagnoses (cases whose first ever HIV diagnosis was in Victoria) and cases previously diagnosed interstate and overseas.

Improving HIV surveillance in Victoria: the role of the "detuned" enzyme immunoassay.

Between 1999 and 2000, new diagnoses of HIV in Victoria (Australia) rose by 41%, from 140 to 197. In this time period, sera from new HIV diagnoses were tested using the Organon Teknika "detuned" enzyme immunoassay (EIA). We compared the results of the detuned EIA with incident infections defined by surveillance (on the basis of a previous negative or indeterminate HIV test and/or a seroconversion illness within the 12 months preceding HIV diagnosis).

Rising HIV infection in Victoria: an analysis of surveillance data.

Objectives: To describe the epidemiology of HIV in Victoria between 1997 and 2002 using HIV surveillance data.

Methods: All HIV diagnoses notified to the Victorian HIV Registry from 1997 to 2002 were described.

Results: The average annual number of HIV notifications rose from 160 during 1997-99 to 216 during 2000-02, with the number of infections from men who have sex with men (MSM) increasing by 41%.

Molecular analysis of human immunodeficiency virus strains associated with a case of criminal transmission of the virus.

An investigation was done of the evidence for transmission of human immunodeficiency virus (HIV) from an HIV-positive man to several male and female sex contacts. Phylogenetic analysis of sequences from the gag and env genes showed a close relationship between the predominant virus strains from the source and 2 contacts. However, the likelihood that a female contact was infected by the source could not be determined, despite contact tracing indicating that this may have occurred.

Hepatitis G virus and fulminant hepatic failure: evidence for transfusion-related infection.

Background/aims: In the majority of cases of fulminant "viral" hepatitis in Australia, no known aetiological agent can be isolated. We have examined the possible role of the recently discovered hepatitis G virus (HGV) in such cases.

Methods: An HGV specific reverse transcription polymerase chain reaction (RT-PCR) was performed on pre- and post-liver transplant serum from 14 patients who were referred for transplantation at our unit between 1989 and 1995 for unexplained fulminant hepatic failure.

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.

Background/aims: The purpose of this study was to investigate possible resistance mutations which arose in the polymerase gene of hepatitis B virus (HBV) in a patient with severe recurrent HBV infection following liver transplantation. The patient's management included antiviral chemotherapy for almost 4 years comprising ganciclovir, foscarnet and famciclovir. In the last 2.

Exposure to hepatitis B and C of tattooists in Victoria in 1984.

Although tattooing is recognized as a risk factor for transmission of hepatitis C, the efficiency with which transmission occurs is unknown. Sera stored from a serosurvey of tattooists undertaken in 1984 to test for human immunodeficiency virus (HIV) provided the opportunity to determine the prevalence of serological markers of hepatitis B virus (HBV) and hepatitis C virus (HCV) in tattooists at that time. The stored sera had been obtained from five unregistered and 36 of 37 (97%) of the registered tattooists operating in 1984.

Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy.

Retransplantation for hepatitis B-related liver allograft failure is rarely successful. Recurrence of infection is almost universal, and the second allograft is invariably lost more rapidly than the first. In a recent multicenter study, only 1 of 20 hepatitis B virus (HBV)-positive patients who underwent liver retransplantation survived beyond 6 months.

Blood-borne virus infections among Australian injecting drug users: implications for spread of HIV.

To describe the epidemiology of infection with hepatitis C virus (HCV), hepatitis B virus (HBV) and human immunodeficiency virus (HIV) among injecting drug users (IDUs) in Australia, in relation to the potential for further spread of HIV in IDUs, a cross-sectional analysis was performed on data from a sample of injecting drug users, correlating markers of exposure to blood-borne viruses with sex, age, sexual orientation, primary current drug injected and duration of injecting in rural and metropolitan Victoria, Australia. The subjects were currently active IDUs from a wide spectrum of age, sex, sexual orientation, geographical location and social background, contacted and recruited through their social networks and from community agencies and prisons by trained peer workers who interviewed and collected blood from them in the field. Sera were tested for antibody to HIV, HCV and hepatitis B core antigen (HBcAg), for hepatitis B surface antigen (HBsAg), and for HCV RNA using reverse transcription and polymerase chain reaction (RT-PCR).

Prevalence of hepatitis C virus markers in Sri Lankan patients with alcoholic cirrhosis.

A high prevalence of antibodies against hepatitis C virus (HCV) has been reported in patients with alcoholic cirrhosis. There are, however, doubts regarding the specificity of the first generation anti-HCV antibody assays used. We prospectively investigated HCV status in 47 Sri Lankan patients with alcoholic cirrhosis.

Hepatitis C virus infection among a cohort of Victorian injecting drug users.

Objective: To describe the epidemiology of infection with hepatitis C virus (HCV) among injecting drug users (IDUs) in Victoria.

Design And Subjects: Subjects were current IDUs from a wide spectrum of age, sex and social background, enrolled in a prospective study of injecting drug use. They were contacted by peer workers through their social networks and through community agencies and prisons, and were regularly followed for interview and blood collection in the field.

The epidemiology of HIV-1 infection in Victoria. The Victorian Collaborative Group on HIV and AIDS Surveillance (VCGHAS).

Objective: To describe the epidemiology of infection with the human immunodeficiency virus type 1 (HIV-1) in Victoria from 1980 to 1991.

Design: Data on HIV-1 infection in Victoria, obtained through routine laboratory-based surveillance, were entered in a database. Missing information was sought by contacting the referring doctor where possible.

Presence of antibodies to human immunodeficiency virus-1 in reference reagents of human origin in diagnostic kits.

We tested 54 reagents of human origin that were included in a number of diagnostic kits to be used as positive or negative control material, and for quality assurance, for the presence of antibodies to human immunodeficiency virus-1 (HIV-1). Of these, 12 (22%) reagents were found to give positive results for antibodies to HIV-1 by enzyme-linked immunosorbent assay and/or supplementary tests. These results suggest that some diagnostic reagents of human origin may be contaminated with HIV-1 and potentially may be infectious.

Control of therapeutic goods produced by recombinant DNA technology.

The Therapeutics Division of the Commonwealth Department of Health is responsible for ensuring the quality, safety, and efficacy of rDNA products intended for human therapeutic use in Australia. The National Biological Standards Laboratory evaluates information on production and quality control submitted by manufacturers, and the Drug Evaluation Section examines the clinical safety and efficacy aspects of product applications. rDNA production methods are considered to be biological processes requiring control of source materials, production methods, and final product for adequate quality assurance of products.

Immunochemical analyses of Australian bluetongue virus serotypes using monoclonal antibodies.

In order to characterize the immunochemical role of bluetongue virus (BTV)-specified proteins and provide reagents capable of defining the serological relatedness of bluetongue (BT) serotypes and their relationship with other orbiviruses, a panel of 16 IgG monoclonal antibodies was raised to the Australian BTV serotypes, isolate CSIRO156 (BTV 1), CSIRO19 (BTV20) and CSIRO154 (BTV21). Analyses of virus-coded polypeptide specificities of these monoclonals using enzyme-linked immunosorbent assay (ELISA), a radioimmunoprecipitation assay (RIPA), and a virus neutralization assay, revealed the outer coat viral protein P2 to have a major role in the neutralization of both CSIRO156 and CSIRO19. Presumptive evidence for the involvement of the P3 protein in the neutralization of CSIRO19 was also obtained.

The major surface glycoprotein of simian rotavirus (SA11) contains distinct epitopes.

The polypeptide specificities on monoclonal antibodies previously derived against the SA11 simian, NIC bovine, and Wa human strains of rotavirus were determined by radioimmunoprecipitation of infected cell lysates. All the monoclonal antibodies derived using NIC and Wa were found to be directed against the major component of the inner capsid, while most of the SA11 monoclones were directed against the major outer capsid glycoprotein. When several SA11 glycoprotein-specific monoclonal antibodies were used in competitive binding studies, four distinct epitopes, which correlated with the functional activities of the antibodies, were defined.

Anti-oxazolone hybridomas and strain distribution of the oxazolone idiotype.

Antibodies produced in the primary response to the hapten 2-phenyloxazolone (OX) express a cross-reactive idiotype in BALB/c and DBA/2 mice. We studied the response in hyperimmunized mice, using ascites produced after multiple immunizations with an OX conjugate and by generating monoclonal antibodies. A competitive radioimmunoassay was developed using a rabbit anti-idiotype antiserum raised against purified hyperimmune anti-OX antibodies.

Derivation of neutralizing monoclonal antibodies against rotavirus.

Monoclonal antibodies were derived against the SA11 simian, NIC bovine, and Wa human rotavirus strains and characterized by enzyme-linked immunosorbent assay, plaque neutralization, and hemagglutination inhibition. Several strain SA11-specific antibodies were found to have neutralizing and hemagglutination-inhibiting capacity.